Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer.
about
HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesisA phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1.Estrogen receptor-negative breast cancer: new insights into subclassification and targetingTargeting autophagy in breast cancer.Regulation of Skp2 levels by the Pim-1 protein kinaseDefinition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancerSmall interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.Treatment options for patients with triple-negative breast cancerDeath-associated protein kinase 1 promotes growth of p53-mutant cancers.Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.Gene expression profiles of estrogen receptor-positive and estrogen receptor-negative breast cancers are detectable in histologically normal breast epitheliumAnalysis of steroid hormone effects on xenografted human NF1 tumor schwann cellsBasal-like and triple-negative breast cancers: searching for positives among many negativesKinome expression profiling and prognosis of basal breast cancersModeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling.Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.Development and validation of a novel platform-independent metastasis signature in human breast cancer.Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancerMolecular basis of triple negative breast cancer and implications for therapy.An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer.Aberrant expression and potential therapeutic target of lysophosphatidic acid receptor 3 in triple-negative breast cancers.Basal breast cancer: a complex and deadly molecular subtypeSystematic Identification and Assessment of Therapeutic Targets for Breast Cancer Based on Genome-Wide RNA Interference TranscriptomesInhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells.Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast CancerPhosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival.Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasionTargeted therapy for breast cancer prevention.MELK kinase holds promise as a new radiosensitizing target and biomarker in triple-negative breast cancer.PTK 7 is a transforming gene and prognostic marker for breast cancer and nodal metastasis involvement.Coordinated regulation of serum- and glucocorticoid-inducible kinase 3 by a C-terminal hydrophobic motif and Hsp90-Cdc37 chaperone complexMELK: a potential novel therapeutic target for TNBC and other aggressive malignancies.Therapeutic Targeting of PTK7 is Cytotoxic in Atypical Teratoid Rhabdoid Tumors.PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.Src family kinases promote silencing of ATR-Chk1 signaling in termination of DNA damage checkpoint.Annotation enrichment analysis: an alternative method for evaluating the functional properties of gene sets.Comparative kinome analysis to identify putative colon tumor biomarkers.Revealing targeted therapeutic opportunities in triple-negative breast cancers: a new strategy.
P2860
Q24598092-EF947304-ECCF-49E5-B452-8374F2C66C31Q30422919-079C0C8E-5D65-4F57-B2D0-B2843CC16A69Q33701389-4A826358-C34E-4FBB-BFE7-3F1777F761DEQ33996918-634BD224-1212-429B-B1ED-9085939E84EDQ34023616-DC7BBA20-B419-468A-A599-528346F78985Q34121488-D7C67C5C-62EE-478B-91B6-BD2789D3136AQ34135362-31482884-6A26-49DA-A561-7506B888C539Q34152071-A40FEF0D-33CA-4539-AA06-408118F4C836Q34331406-BA1111C5-A7A5-4084-8F9F-19880C6F2352Q34480753-3621809B-5D8E-405C-AEC8-505F39B63F28Q34654793-BDA8738C-315B-406F-A10F-C1B5C188711FQ34686883-8CB7D50A-27D2-4D64-95A1-569B363D76A3Q34979170-4C8941BD-DDE2-4BEC-852E-435624516134Q35005793-8CB155E1-40E0-444E-B9BC-D77C12DA0A4EQ35166659-BC208DD4-4CBB-44DE-9AA9-D78652698A6FQ35354276-B62129EE-85DE-4C1A-A423-437520D2C62DQ35558993-BB44ACBA-2214-4666-B43C-4C299625E670Q35606889-7D3EF406-E69F-43BF-B609-84ABDE13C075Q35642344-7C306FEC-7CAF-4310-B882-D2168656DA54Q35684581-55EE2EFD-5B1A-4722-951A-CA2AEEE0A8F7Q35872681-8857837C-E243-49FE-A0A9-FE5D0A9D2F12Q35908698-7C8FA8EA-E30F-4AE4-869C-5592AF3B53C3Q35931900-69BE5BD4-A5CD-487E-8EF1-9DAA230041B8Q36293047-5F666EE7-7B1A-4AA0-A20D-1085F9B157C2Q36299754-E71E917A-26C5-4DEA-A713-8F3BFBBF9122Q36583169-1E5187C9-21C2-4097-9DE2-45F8728B0EA1Q36679783-557680EC-B27A-4E9F-93A5-C00F63726FC8Q36918028-2F383159-9806-4C2C-A507-9827B0D4BFBFQ37131923-7B1FE151-BAB3-481D-9FDC-5F0EDDB69D13Q37190825-7D9AD1EC-EB21-4FD1-A99C-034F23BFF38FQ37411211-7A99259C-D627-4224-9088-CB404D20D533Q37444908-210B0890-8B9C-4669-A367-6C2686B824CCQ37596323-DF0E1EDA-C345-4683-9C7D-4D4EB6747563Q38648606-BF1CAE9E-6A7C-4EA9-A2E8-E0BDF5E293CCQ38690911-F482263F-AA79-4C25-A978-DC49D24BAA85Q38735131-4DFB78BF-F139-48A3-98CB-FF14DD9323F2Q39145490-358C6B86-58D1-47B2-BB0A-C962FD10C720Q41786087-915DD4DC-C4ED-43EB-9907-05771EE10468Q42250395-E6DB1CF3-964E-48D8-ADCD-4C6515405308Q42736627-7714A70B-A612-4374-9651-5FE2B6F3F096
P2860
Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Identification of novel kinase ...... ceptor-negative breast cancer.
@en
Identification of novel kinase ...... ceptor-negative breast cancer.
@nl
type
label
Identification of novel kinase ...... ceptor-negative breast cancer.
@en
Identification of novel kinase ...... ceptor-negative breast cancer.
@nl
prefLabel
Identification of novel kinase ...... ceptor-negative breast cancer.
@en
Identification of novel kinase ...... ceptor-negative breast cancer.
@nl
P2093
P2860
P50
P1476
Identification of novel kinase ...... ceptor-negative breast cancer.
@en
P2093
Ashley M Herrick
Carolina Gutierrez
Corey Speers
Jenny Chang
Krystal Sexton
Powel Brown
Susan Hilsenbeck
P2860
P304
P356
10.1158/1078-0432.CCR-09-1107
P407
P577
2009-10-06T00:00:00Z